Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 4, 2014, Pages 780-783

  Shi, Jing ^a   Van De Stadt, Lotte A ^b,c   Levarht, E W Nivine ^a   Huizinga, Tom W J ^a   Hamann, Dörte ^d   Van Schaardenburg, Dirkjan ^b,e   Toes, René E M ^a   Trouw, Leendert A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Jan Van Breemen Research Institute   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Division of Diagnostic Services   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARBAMYLATED CYCLIC CITRULLINATED PEPTIDE 2 ANTIBODY; CARBAMYLATED FETAL CALF SERUM ANTIBODY; CARBAMYLATED FIBRINOGEN ANTIBODY; CARBAMYLATED PROTEIN ANTIBODY; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ASYMPTOMATIC DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANT-CCP; AUTOANTIBODIES; EARLY RHEUMATOID ARTHRITIS; RHEUMATOID FACTOR;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BLOOD PROTEINS; CARBAMATES; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PRODROMAL SYMPTOMS; RHEUMATOID FACTOR; TIME FACTORS;

EID: 84895463561     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204154     Document Type: Article

References (20)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 1925;376:1094-108.
2. Breedveld F. The value of early intervention in RA-a window of opportunity. Clin Rheumatol 2011;30:33-9.
3. Klareskog L, Ronnelid J, Lundberg K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Ann Rev Immunol 2008;26:651-75. (Pubitemid 351600388)
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
5. Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008;67:801-7. (Pubitemid 351829380)
6. Nielen MM, van SD, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6. (Pubitemid 38198821)
7. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9. (Pubitemid 37280601)
8. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci 2011;108:17372-7.
9. Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012;12:318-22.
10. Shi J, van de Stadt LA, Levarht EWN, et al. Anti carbamylated protein antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013;65:911-15.
11. van de Stadt LA, de Koning MHMT, van de Stadt RJ, et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011;63:3226-33.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
13. Shi J, Willemze A, Janssen GMC, et al. Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the "AMC-Senshu" method. Ann Rheum Dis 2013;72:148-50.
14. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122:1791-802.
15. Laurent L, Clavel C, Lemaire O, et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis 2011;70:1052-9.
16. Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923-31.
17. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
18. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000-8.
19. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010;69:490-4.
20. Daha NA, Banda NK, Roos A, et al. Complement activation by (auto-) antibodies. Mol Immunol 2011;48:1656-65.